Evidence map›Paper›PMID 38731981›Full record

ArticleInternational journal of molecular sciences2024

CYP7B1 as a Biomarker for Prostate Cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in Prostate Cancer Patients-Diamond Study).

Giorgio Ivan Russo, Emil Durukan, Maria Giovanna Asmundo, Arturo Lo Giudice, Serena Salzano, Sebastiano Cimino, Antonio Rescifina, Mikkel Fode, Ali Saber Abdelhameed, Rosario Caltabiano and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giorgio Ivan RussoUrology Section, Department of Surgery, University of Catania, 95123 Catania, Italy.ORCID 0000-0003-4687-7353
Emil DurukanDepartment of Urology, Copenhagen University Hospital, Herlev Hospital, 2730 Copenhagen, Denmark.ORCID 0000-0001-9221-8944
Maria Giovanna AsmundoUrology Section, Department of Surgery, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-8248-6857
Arturo Lo GiudiceUrology Section, Department of Surgery, University of Catania, 95123 Catania, Italy.ORCID 0000-0003-1987-929X
Serena SalzanoDepartment of Medical and Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy.
Sebastiano CiminoUrology Section, Department of Surgery, University of Catania, 95123 Catania, Italy.
Antonio RescifinaDepartment of Drug Sciences, University of Catania, 95125 Catania, Italy.ORCID 0000-0001-5039-2151
Mikkel FodeDepartment of Urology, Copenhagen University Hospital, Herlev Hospital, 2730 Copenhagen, Denmark.
Ali Saber AbdelhameedDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-5910-2832
Rosario CaltabianoDepartment of Medical and Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-8591-8010
Giuseppe BroggiDepartment of Medical and Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy.ORCID 0000-0003-2576-6523

Funding

University of Catania This research was funded by Linea 3-Piano di incentivi per la ricerca di Ateneo 2020/2022 (Pia.ce.ri.) of the University of Catania and the HEAL ITALIA (Health Extended ALliance for In-novative Therapies and Advanced Lab-research through Integrated Approa
6 · The paper itself

Abstract

We aimed to analyze the association between CYP7B1 and prostate cancer, along with its association with proteins involved in cancer and metabolic processes. A retrospective analysis was performed on 390 patients with prostate cancer (PC) or benign prostatic hyperplasia (BPH). We investigated the interactions between CYP7B1 expression and proteins associated with PC and metabolic processes, followed by an analysis of the risk of biochemical recurrence based on CYP7B1 expression. Of the 139 patients with elevated CYP7B1 expression, 92.8% had prostate cancer. Overall, no increased risk of biochemical recurrence was associated with CYP7B1 expression. However, in a non-diabetic subgroup analysis, higher CYP7B1 expression indicated a higher risk of biochemical recurrence, with an HR of 1.78 (CI: 1.0-3.2,

Indexed as

Biomarkers, TumorCytochrome P450 Family 7Prostatic NeoplasmsAgedDisease ProgressionHumansImmunohistochemistryMaleMiddle AgedNeoplasm Recurrence, LocalProstatic HyperplasiaRetrospective StudiesSteroid HydroxylasesTissue Array AnalysisBiomarkers, TumorCYP7B1 protein, humanCytochrome P450 Family 7Steroid Hydroxylasesbiochemical recurrenceCYP7B1prognosisprostate cancerWarburg

Identifiers

PMID38731981
PMCPMC11083792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.